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of standardization, were among the first to initiate new
pharmacoeconomic and pharmacoepidemiological devel-
opments. At the third stage, the establishment of a stan-
dardization service is envisaged. In addition to regulatory
documentation development proper, the service will be en-
gaged in putting these standards and specifications into
practice and in analyzing the results on the introduction of
specific regulatory documents. The I. M. Sechenov Moscow
Medical Academy (its Laboratory of Outcomes and Stan-
dardization Research Problems) has been appointed the
central research institution to deal with standardization
problems. It is entrusted with the duties of a coordinator of
research developments, an expert in the existing documents
and a developer of a standardizing base (now lacking). In
1999, a conference is to be held and a scientific journal cov-
ering standardization problems will begin publication.
W20
STANDARD PROCEDURES FOR ECONOMIC 
EVALUATION: USING A COMPUTER PROGRAM 
FOR REPORTING ECONOMIC EVALUATIONS 
RESULTS (REER)
Rovira J1,2, Brosa M2, Abbas I1,2
1University of Barcelona, Barcelona, Spain; 2Soikos,
Barcelona, Spain
This workshop is intended for individuals with a basic un-
derstanding of the concepts and terminology of economic
evaluation of healthcare who want to discuss applied stan-
dardization methodologies. Several software tools are
available to assist in the development of pharmacoeco-
nomic models. However, the lack of a standardized set of
rules to present economic evaluation results may limit the
comparability of studies carried out by different analysts.
The objective of this session is to define a set of standard-
ized procedures to improve the comparability of results of
economic evaluation studies by means of user-friendly
computer software for Reporting Economic Evaluation
Results (the REER software). Two different prototypes
will be presented: an application aimed at presenting eco-
nomic evaluation results; and a health costs database
(HCD). The main program (REER) is divided into three
basic modules: 1) definition of options (treatment/interven-
tion comparators, subjects); 2) data inputs (resources, unit
costs, health outcomes, discounting and sensitivity analy-
sis); and 3) outputs (differences in costs and effects, domi-
nance analysis, incremental analysis, and sensitivity analy-
sis). A prototype version of the REER software will be
presented by means of two published pharmacoeconomic
analyses. The Health Costs Database Software (HCDS) en-
ables the collection, categorization, and storage of unit
cost data to be used in different types of studies (e.g., cost
analysis, economic evaluation). The database, which sim-
plifies the retrieval of average and actualized cost figures,
makes rapidly available updated unit cost data which can
be used directly (e.g., within the REER software), as a first
calculation, or can be contrasted with later cost estima-
tions. Problems with obtaining standardized results of eco-
nomic evaluation studies and the usefulness of programs
such as the REER software will be examined, and future
development of complete and fully operational software
tools will be discussed.
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The DARTS database is a validated, population-based reg-
ister of 9,000 patients with diabetes in the population of
Tayside, Scotland, compiled by the record-linkage of inde-
pendent datasets. These include diabetes clinic records,
hospital activity data, biochemistry results, and a database
of dispensed prescriptions. The database can be used for
epidemiological, outcomes, and health services research.
Diabetes is a disease with high morbidity and mortality,
for which treatments are onerous and time-consuming.
Thus the nonclinical or psychological dimension should
not be ignored, and so the incorporation of quality of life
measures into DARTS has been proposed. A wide range of
disease-specific and generic measures that tap into many
different facets of quality of life have already been used in
diabetes. The challenge is to identify a valid and reliable
package of measures that could be practical for the dia-
betic patients of Tayside. In this workshop, the approach
adopted to identify such a package for routine use in
DARTS will be described and discussed. It will include a
critical review of quality of life measures that have already
been used in diabetic patients, the results of a survey of di-
abetic patients and diabetic health professionals to identify
those aspects of quality of life deemed to be particularly
relevant to diabetes, and a discussion of the validation of
the measures chosen in a pilot group of patients. The
workshop would thus be of interest to researchers working
with quality of life outcome measures, and/or to those in-
volved in the development and application of disease-
specific databases.
W13
THE USE OF PROXIES TO COLLECT 
HEALTHCARE RESOURCES AND QUALITY OF 
LIFE DATA
Crawford B1, Evans C2, Abetz L3
1MAPI Values, Boston, MA, US; 2Astra Pharmaceuticals, 
Westborough, MA, US; 3MAPI Values, Cheshire, UK
The measurement of a product’s intrinsic value has become
an essential part of a new technology’s reimbursement and
marketing strategy. The key tactics in the evaluation of a
